ANDREONE, P. Et Al. 2014. ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection. GASTROENTEROLOGY , vol.147, no.2 , 359-366.

ANDREONE, P., COLOMBO, M. G., ENEJOSA, J. V., Koksal, I., FERENCI, P., MAIERON, A., ... Muellhaupt, B.(2014). ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection. GASTROENTEROLOGY , vol.147, no.2, 359-366.

ANDREONE, İFTAHAR Et Al. "ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection," GASTROENTEROLOGY , vol.147, no.2, 359-366, 2014

ANDREONE, İFTAHAR Et Al. "ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection." GASTROENTEROLOGY , vol.147, no.2, pp.359-366, 2014

ANDREONE, P. Et Al. (2014) . "ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection." GASTROENTEROLOGY , vol.147, no.2, pp.359-366.

@article{article, author={İFTAHAR KÖKSAL Et Al. }, title={ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection}, journal={GASTROENTEROLOGY}, year=2014, pages={359-366} }